Metformin Before the ICU: A Surprising Kidney Signal Challenges the Usual Narrative

Metformin is often approached with caution when kidney function declines. However, a new study examining the relationship between metformin use and acute kidney injury has uncovered a surprising association. Among more than 3,000 intensive care unit (ICU) patients with type 2 diabetes, those who used metformin before admission had lower odds of developing acute kidney injury (AKI). The findings also suggest that medication history may improve predictions of kidney complications. Could a familiar diabetes medication provide more information about kidney risk than previously recognized? The answer is promising but requires careful interpretation.

Table of Contents

1. Metformin and Acute Kidney Injury: What the ICU Study Found
2. How Metformin History Improved AKI Risk Prediction
3. Why Lower AKI Odds Do Not Prove Metformin Protects Kidneys
4. What the Findings Mean for Diabetes and Kidney Safety
5. Conclusion
6. Frequently Asked Questions

Metformin and Acute Kidney Injury: What the ICU Study Found

Published October 10, 2026, in BMC Nephrology, the retrospective study examined 3,145 ICU patients with type 2 diabetes. Researchers used the MIMIC-IV database to explore whether long-term metformin use before hospitalization was associated with AKI.

Of these patients, 1,245 met the study's AKI criteria, while 1,059 had used metformin before admission. The researchers compared medication exposure with kidney outcomes while accounting for several clinical characteristics.

Importantly, they used propensity score matching to create 760 comparable patient pairs. This method helps reduce differences between treatment groups, although it cannot eliminate every source of bias.

In the matched analysis, previous metformin use was associated with significantly lower odds of AKI. The reported odds ratio was 0.392, with a 95% confidence interval of 0.306 to 0.502.

That represents approximately 61% lower odds in the matched comparison, not a proven 61% reduction in risk caused by metformin.

Additionally, the association remained statistically significant after further adjustment for selected clinical variables. A separate sensitivity analysis excluding patients with AKI at their first ICU admission produced a similar finding.

These results raise important questions about how diabetes treatment history relates to kidney outcomes during critical illness.

How Metformin History Improved AKI Risk Prediction

Beyond examining kidney injury outcomes, investigators explored whether previous metformin use could improve clinical risk prediction.

They developed several models, including standard logistic regression, LASSO logistic regression, and XGBoost, a machine learning approach designed to identify complex patterns in data.

Each model was evaluated with and without metformin history.

Overall, adding metformin exposure improved discrimination and prediction accuracy across several comparisons. In the main development cohort, the XGBoost model incorporating metformin achieved an area under the receiver operating characteristic curve (ROC-AUC) of 0.863.

This measurement indicates how effectively a model distinguishes patients who experience AKI from those who do not. Higher values generally indicate stronger discrimination.

Meanwhile, the model's Brier score of 0.148 provided another measure of prediction quality, reflecting how closely estimated probabilities matched actual outcomes.

Researchers also tested the models in an independent hospital cohort of 100 patients. There, the clinical logistic regression model incorporating metformin performed best, achieving an ROC-AUC of 0.955.

However, this small validation group limits confidence in how consistently the results would perform across larger hospitals.

The findings suggest that medication history may add useful information when assessing the risk of acute kidney injury. Nevertheless, additional prospective validation is necessary before these prediction tools can guide routine ICU decisions.

Why Lower AKI Odds Do Not Prove Metformin Protects Kidneys

The association between metformin use before hospitalization and lower odds of acute kidney injury deserves attention. Still, observational findings should never be confused with proof of a treatment effect.

Patients prescribed metformin may differ from nonusers in several important ways. For example, clinicians often avoid metformin in individuals with advanced kidney disease or other conditions that increase treatment risks.

Consequently, patients already receiving metformin may have had better baseline kidney function or fewer serious health problems before hospitalization.

Although propensity score matching reduces measured differences, unmeasured factors can still influence the results.

This concern is particularly important when interpreting medications patients were taking before ICU admission. Previous use does not demonstrate that treatment was continued during hospitalization, nor does it establish that continued dosing would be beneficial.

Earlier research has explored metformin's effects on inflammation and cellular energy regulation. These mechanisms provide possible explanations worth investigating, but they do not establish kidney protection in critically ill patients.

Nevertheless, translating laboratory observations into clinical treatment recommendations requires stronger evidence.

Ultimately, randomized trials or carefully designed prospective studies would be needed to determine whether metformin itself meaningfully changes AKI risk.

What the Findings Mean for Diabetes and Kidney Safety

The new research should encourage thoughtful medication review rather than changes to established safety precautions.

Metformin remains a widely used treatment for type 2 diabetes because it effectively lowers blood glucose, has a low risk of hypoglycemia when used alone, and is generally affordable.

However, kidney function plays a central role in determining whether treatment is appropriate.

According to the American Diabetes Association's 2026 Standards of Care, metformin is contraindicated when the estimated glomerular filtration rate (eGFR) falls below 30 mL/min/1.73 m².

Furthermore, treatment initiation is not recommended when eGFR is below 45 mL/min/1.73 m². Clinicians should reassess the benefits and risks of continued therapy when kidney function falls beneath that threshold.

During acute illness, additional precautions become necessary.

Sepsis, dehydration, poor circulation, and AKI may reduce metformin clearance. As a result, the medication can accumulate, increasing concern about metformin-associated lactic acidosis, a rare but potentially life-threatening complication.

For this reason, clinicians commonly withhold metformin during significant acute illness or AKI until the patient stabilizes and kidney function can be reassessed.

The new findings do not justify continuing metformin when contraindications are present.

Diabetes in Control has previously discussed these concerns in its review of metformin use during acute renal failure.

For clinical teams, the practical message is straightforward: document metformin use before ICU admission, evaluate current kidney function, and reassess treatment as a patient's condition changes.

Conclusion

New research examining metformin use and acute kidney injury presents an intriguing finding: patients with type 2 diabetes who took metformin before ICU admission had lower odds of AKI.

Additionally, incorporating medication history improved several kidney injury prediction models, suggesting a potentially useful role in future risk assessment.

However, these associations do not establish that metformin prevents AKI. Established precautions regarding acute illness, reduced kidney function, and lactic acidosis remain essential.

For clinicians, the most important takeaway is to recognize the value of medication history while continuing individualized, evidence-based diabetes care.

Frequently Asked Questions

1. Does metformin prevent acute kidney injury?

Current evidence does not establish that metformin prevents AKI. The 2026 observational study identified an association between previous metformin use and lower AKI odds, but it could not demonstrate causation.

2. Can patients continue metformin during acute kidney injury?

Metformin is generally withheld during AKI or significant acute illness because reduced kidney clearance may increase the risk of drug accumulation and lactic acidosis. Treatment should be reconsidered after clinical stabilization and kidney function reassessment.

3. What kidney function level makes metformin unsafe?

Metformin is contraindicated when eGFR is below 30 mL/min/1.73 m². Starting treatment is not recommended below 45 mL/min/1.73 m², and patients with moderately reduced kidney function may require closer monitoring and dose adjustments.

4. Why was metformin associated with lower AKI odds?

Several explanations are possible, including differences in patients' baseline health, prescribing patterns, and potential biological effects. However, the study could not determine which factors accounted for the association.

5. Could metformin history improve ICU kidney injury prediction?

Possibly. Researchers found that including prior metformin use improved several prediction models. Larger prospective studies are needed to determine whether these improvements translate into better clinical outcomes.

This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.